Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Point Capital Navigator Fund

Tracked across 1 events · 21 articles · First seen Sep 08, 2026 · Last active Sep 11, 2026

Sentiment
-10
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 -10
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Novartis and Roche shareholder whose lead manager Gillian Hollenstein said confidence will take time to return and that smaller bolt-on acquisitions would have been preferable.
Sep 08, 2026 · 21 articles
ERGEN INTELLIGENCE
Track Point Capital Navigator Fund live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.